Y-mAbs Therapeutics Inc. (YMAB)
NASDAQ: YMAB
· Real-Time Price · USD
4.82
-0.09 (-1.83%)
At close: Jun 26, 2025, 11:52 AM
-1.83% (1D)
| Bid | 4.79 |
| Market Cap | 218.1M |
| Revenue (ttm) | 88.66M |
| Net Income (ttm) | -28.23M |
| EPS (ttm) | -0.64 |
| PE Ratio (ttm) | -7.52 |
| Forward PE | -4.88 |
| Analyst | Buy |
| Ask | 4.82 |
| Volume | 41,250 |
| Avg. Volume (20D) | 237,882 |
| Open | 4.92 |
| Previous Close | 4.91 |
| Day's Range | 4.73 - 5.19 |
| 52-Week Range | 3.55 - 16.11 |
| Beta | 0.51 |
About YMAB
undefined
Industry n/a
Sector n/a
IPO Date n/a
Employees NaN
Stock Exchange n/a
Ticker Symbol YMAB
Website n/a
Analyst Forecast
According to 0 analyst ratings, the average rating for YMAB stock is "n/a." The 12-month stock price forecast is $n/a, which is a decrease of 0% from the latest price.
Stock ForecastsNext Earnings Release
Y-mAbs Therapeutics Inc. is scheduled to release its earnings on Aug 11, 2025,
before market opens.
Analysts project revenue of ... Unlock content with Pro Subscription
Analysts project revenue of ... Unlock content with Pro Subscription
6 months ago
-0.77%
Y-MAbs Therapeutics shares are trading higher afte...
Unlock content with
Pro Subscription
10 months ago
+10.63%
Y-mAbs Therapeutics shares are trading. The stock may be rebounding after falling earlier in the week on weak earnings and guidance.
1 month ago · seekingalpha.com
Y-mAbs Therapeutics, Inc. (YMAB) Q1 2025 Earnings Call TranscriptY-mAbs Therapeutics, Inc. (NASDAQ:YMAB ) Q1 2025 Earnings Conference Call May 13, 2025 8:00 AM ET Company Participants Courtney Dugan - Vice President, Head of Investor Relations Michael Rossi - Presi...
